Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Grilfols announces first phase-II Alpha-1 HC aerosol enrolment

Grilfols announces first phase-II Alpha-1 HC aerosol enrolment

12th October 2012

Grifols has announced its first patient has been enrolled and dosed in its phase-II trial of Alpha-1 HC aerosol to treat cystic fibrosis.

The study evaluates the safety of tolerability of Alpha-1 HC aerosol in patents with this condition.

Cystic fibrosis is an inherited disease that causes progressive decline in the function of the lungs, including acute episodes of worsening respiratory symptoms and lung infections that can prove fatal.

The trial looks into two doses of Alpha-1 HC aerosol – which is an inhaled formulation of Grifols' alpha1-proteinase inhibitor.

Grifols currently leads the global market with its intravenous alpha1-protenaise inhibitor for the treatment of alpha1-antitrypsin deficiency, which is a rare condition that can cause emphysema due to low circulation levels of the alpha1 protein in the lungs.

"Our goal is to continually develop new therapies that will improve the quality of life and prognosis for individuals with cystic fibrosis," stated Dr Amit Gaggarm, associate professor of medicine at the University of Alabama, which is one of the study sites.ADNFCR-8000103-ID-801468226-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.